Tags

Type your tag names separated by a space and hit enter

Characterization of the phosphodiesterase inhibition by 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and its sulfide- and sulfone derivatives in myocardial preparations from failing human hearts.
Arzneimittelforschung. 1995 Jul; 45(7):771-6.A

Abstract

The effects of HN-10200 (2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo(4,5-c)-pyridine HCl) and its derivatives HN-10201-sulfide and HN-10202-sulfone on the activities of the phosphodiesterase (PDE) isoenzyme activities isolated from ventricular myocardium of failing human hearts (end-stage myocardial failure, NYHA IV) were investigated. Four PDE isoenzymes (PDE I-IV) were separated by DEAE-sepharose chromatography. Milrinone, 3-isobutyl-1-methylxanthine (IBMX), and a derivative of pimobendan (2-(4-hydroxyphenyl)-5-(5-methyl-3-oxo-4,5-dihydro-2H-6-pyridazinyl)- benzimidazole HCl, PiD) were studied for comparison. Furthermore, the influence of HN-10200 on force of contraction and cAMP content of ventricular trabeculae of these hearts were determined. HN-10200 inhibited the activities of PDE I-IV concentration-dependently. The IC50 values were (mumol/l): 218.7, 283.1, 119.6, and 85.8 for PDE I-IV, respectively. The IC50 values of its derivatives were in the same range, i.e. the parent compound or its derivatives inhibited the PDE isoenzymes nonselectively. IBMX also inhibited PDE I-IV nonselectively, but was about ten times more potent based on IC50 values. In contrast, PiD was the most selective and potent PDE III inhibitor tested. Milrinone inhibited both, PDE III and IV, up to two orders of magnitude more potently than PDE I and II, HN-10200 (30 mumol/l) only marginally and insignificantly increased force of contraction and cAMP content of the ventricular trabeculae. Thus, HN-10200 and it's derivatives HN-10201-sulfide and HN-10202-sulfone are nonselective inhibitors of myocardial PDE I-IV. HN-10200 revealed only neglectable positive inotropic effects in preparations from failing human heart.

Authors+Show Affiliations

Bethke T
Pharmakologisches Institut, Universitäts-Krankenhaus Eppendorf, Universität Hamburg, Germany.
Klimkiewicz A
No affiliation info available
Meyer W
No affiliation info available
Schumacher C
No affiliation info available
Schmitz W
No affiliation info available
Scholz H
No affiliation info available
Starbatty J
No affiliation info available
Wenzlaff H
No affiliation info available
Zimmermann W
No affiliation info available

MeSH

1-Methyl-3-isobutylxanthineAdultChromatography, DEAE-CelluloseCyclic AMPFemaleHeart FailureHumansImidazolesIn Vitro TechniquesIsoenzymesMaleMiddle AgedMilrinoneMyocardial ContractionMyocardiumPhosphodiesterase InhibitorsPhosphoric Diester HydrolasesPyridinesPyridonesSulfidesSulfones

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8573220

Citation

Bethke, T, et al. "Characterization of the Phosphodiesterase Inhibition By 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and Its Sulfide- and Sulfone Derivatives in Myocardial Preparations From Failing Human Hearts." Arzneimittel-Forschung, vol. 45, no. 7, 1995, pp. 771-6.
Bethke T, Klimkiewicz A, Meyer W, et al. Characterization of the phosphodiesterase inhibition by 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and its sulfide- and sulfone derivatives in myocardial preparations from failing human hearts. Arzneimittelforschung. 1995;45(7):771-6.
Bethke, T., Klimkiewicz, A., Meyer, W., Schumacher, C., Schmitz, W., Scholz, H., Starbatty, J., Wenzlaff, H., & Zimmermann, W. (1995). Characterization of the phosphodiesterase inhibition by 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and its sulfide- and sulfone derivatives in myocardial preparations from failing human hearts. Arzneimittel-Forschung, 45(7), 771-6.
Bethke T, et al. Characterization of the Phosphodiesterase Inhibition By 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and Its Sulfide- and Sulfone Derivatives in Myocardial Preparations From Failing Human Hearts. Arzneimittelforschung. 1995;45(7):771-6. PubMed PMID: 8573220.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Characterization of the phosphodiesterase inhibition by 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and its sulfide- and sulfone derivatives in myocardial preparations from failing human hearts. AU - Bethke,T, AU - Klimkiewicz,A, AU - Meyer,W, AU - Schumacher,C, AU - Schmitz,W, AU - Scholz,H, AU - Starbatty,J, AU - Wenzlaff,H, AU - Zimmermann,W, PY - 1995/7/1/pubmed PY - 1995/7/1/medline PY - 1995/7/1/entrez SP - 771 EP - 6 JF - Arzneimittel-Forschung JO - Arzneimittelforschung VL - 45 IS - 7 N2 - The effects of HN-10200 (2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo(4,5-c)-pyridine HCl) and its derivatives HN-10201-sulfide and HN-10202-sulfone on the activities of the phosphodiesterase (PDE) isoenzyme activities isolated from ventricular myocardium of failing human hearts (end-stage myocardial failure, NYHA IV) were investigated. Four PDE isoenzymes (PDE I-IV) were separated by DEAE-sepharose chromatography. Milrinone, 3-isobutyl-1-methylxanthine (IBMX), and a derivative of pimobendan (2-(4-hydroxyphenyl)-5-(5-methyl-3-oxo-4,5-dihydro-2H-6-pyridazinyl)- benzimidazole HCl, PiD) were studied for comparison. Furthermore, the influence of HN-10200 on force of contraction and cAMP content of ventricular trabeculae of these hearts were determined. HN-10200 inhibited the activities of PDE I-IV concentration-dependently. The IC50 values were (mumol/l): 218.7, 283.1, 119.6, and 85.8 for PDE I-IV, respectively. The IC50 values of its derivatives were in the same range, i.e. the parent compound or its derivatives inhibited the PDE isoenzymes nonselectively. IBMX also inhibited PDE I-IV nonselectively, but was about ten times more potent based on IC50 values. In contrast, PiD was the most selective and potent PDE III inhibitor tested. Milrinone inhibited both, PDE III and IV, up to two orders of magnitude more potently than PDE I and II, HN-10200 (30 mumol/l) only marginally and insignificantly increased force of contraction and cAMP content of the ventricular trabeculae. Thus, HN-10200 and it's derivatives HN-10201-sulfide and HN-10202-sulfone are nonselective inhibitors of myocardial PDE I-IV. HN-10200 revealed only neglectable positive inotropic effects in preparations from failing human heart. SN - 0004-4172 UR - https://www.unboundmedicine.com/medline/citation/8573220/Characterization_of_the_phosphodiesterase_inhibition_by_2__3_methoxy_5_methylsulfinyl_2_thienyl__1H_imidazo__45_c__pyridine_HCl_and_its_sulfide__and_sulfone_derivatives_in_myocardial_preparations_from_failing_human_hearts_ L2 - https://medlineplus.gov/heartfailure.html DB - PRIME DP - Unbound Medicine ER -

Related Citations

More